⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17592090 | 0.65 | — | — | |
| SCHEMBL16539508 | 0.61 | — | — | |
| SCHEMBL1246479 | 0.61 | — | — | |
| SCHEMBL17209859 | 0.61 | — | — | |
| SCHEMBL21397767 | 0.60 | — | — | |
| SCHEMBL18306534 | 0.60 | — | — | |
| Bromide SCHEMBL11652645 | 0.60 | — | — | |
| SCHEMBL5223021 | 0.59 | — | — | |
| SCHEMBL15297272 | 0.58 | — | — | |
| SCHEMBL6656712 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207219-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2012-06-26 | — | — | US | disclosed |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-20100120890-A1 | ION CHANNEL MODULATING ACTIVITY I | CARDIOME PHARMA CORP. (CA) | 2010-05-13 | — | — | US | disclosed |
| US-7674820-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2010-03-09 | — | — | US | disclosed |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-7507545-B2 | Ion channel modulating activity method | CARDIOME PHARMA CORP. (CA) | 2009-03-24 | — | — | US | disclosed |
| US-20060199848-A9 | Cardiovascular disorders; antiarrhythmai agenst; sodium channel moderators; potassium channel moderators; prevent fibrillation | CARDIOME PHARMA CORP. (CA) | 2006-09-07 | — | — | US | disclosed |
| US-20060135536-A9 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2006-06-22 | — | — | US | disclosed |
| US-20050119315-A1 | Ion channel modulating activity II | CARDIOME PHARMA CORP. (CA) | 2005-06-02 | — | — | US | disclosed |
| US-20050070552-A1 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2005-03-31 | — | — | US | disclosed |
| WO-2005018635-A2 | ION CHANNEL MODULATING ACTIVITY I | CARDIOME PHARMA CORP. (CA) | 2005-03-03 | — | — | WO | disclosed |
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | JOHN HOPKINS UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| US-6569862-B1 | Adminstering xanthine oxidase inhibitor such as allopurinol | JOHNS HOPKINS UNIVERSITY | 2003-05-27 | — | — | US | disclosed |
| EP-1044002-A4 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | UNIV JOHNS HOPKINS (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6191136-B1 | ADMINISTERING XANTHINE OXIDASE INHIBITOR | JOHNS HOPKINS UNIVERSITY | 2001-02-20 | — | — | US | disclosed |
| EP-1044002-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999024038-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5674887-A | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1997-10-07 | — | — | US | disclosed |
| US-5436258-A | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0587378-A1 | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |